
## Johannes Falke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5543071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics and pharmacodynamics of intravesical and intravenous TMX-101 and TMX-202 in a F344 rat model. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 242.e1-242.e7.	1.6	2
2	Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. International Journal of Hyperthermia, 2018, 34, 988-993.	2.5	14
3	A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model. World Journal of Urology, 2018, 36, 1719-1725.	2.2	7
4	Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model. BioMed Research International, 2018, 2018, 1-7.	1.9	27
5	Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2015, 13, 204-209.e2.	1.9	17
6	Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World Journal of Urology, 2015, 33, 1411-1417.	2.2	10
7	The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: An in vitro study. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 49.e1-49.e6.	1.6	9
8	Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2013, 189, 2077-2082.	0.4	35
9	Contemporary management of low-risk bladder cancer. Nature Reviews Urology, 2011, 8, 42-49.	3.8	23
10	Perioperative management of nonmuscle-invasive bladder cancer. Current Opinion in Urology, 2011, 21, 403-408.	1.8	2